PepGen Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Corporate DevelopmentsGlobeNewsWire • 03/06/24
PepGen Announces Clearance of CTA by UK Medicines & Healthcare Products Regulatory Agency to Begin CONNECT2-EDO51, a Phase 2 Clinical Trial designed to support potential accelerated approval of PGN-EDO51 for the Treatment of Duchenne Muscular DystrophyGlobeNewsWire • 03/04/24
PepGen Receives U.S. FDA Fast Track Designation for PGN-EDODM1 for the Treatment of Myotonic Dystrophy Type 1GlobeNewsWire • 02/20/24
PepGen Announces Pricing of $80.1 Million Underwritten Offering of Common StockGlobeNewsWire • 02/07/24
PepGen Announces First Patient Dosed in CONNECT1-EDO51 Phase 2 Clinical Trial of PGN-EDO51 for Duchenne Muscular Dystrophy Patients Amenable to Exon 51 SkippingGlobeNewsWire • 01/08/24
PepGen Announces First Patient Dosed in Phase 1 FREEDOM-DM1 Clinical Trial of PGN-EDODM1 for Myotonic Dystrophy Type 1 (DM1)GlobeNewsWire • 12/18/23
PepGen Reports Third Quarter 2023 Financial Results and Recent Corporate DevelopmentsGlobeNewsWire • 11/08/23
PepGen Inc. Announces FDA has Lifted the Clinical Hold on its Investigational New Drug Application for FREEDOM-DM1 Phase 1 Study of PGN-EDODM1 for Myotonic Dystrophy Type 1 (DM1)GlobeNewsWire • 10/12/23
PepGen Announces Upcoming Presentations at the 28th Annual Congress of the World Muscle Society and the World Congress of NeurologyGlobeNewsWire • 09/27/23
PepGen Inc. Announces Clearance of CTA by Health Canada to Begin the FREEDOM-DM1 Phase 1 Study of PGN-EDODM1 in Patients with Myotonic Dystrophy Type 1GlobeNewsWire • 09/06/23
PepGen Inc. Presents PGN-EDODM1 Preclinical Data Supporting the Company's Enhanced Delivery Oligonucleotide Platform and PGN-EDODM1 Program at Two Medical ConferencesGlobeNewsWire • 09/06/23
PepGen Announces Presentations at the 2023 Myotonic Dystrophy Foundation Annual Conference, Ottawa Neuromuscular Disease Meeting, and H.C. Wainwright 25th Annual Global Investment ConferenceGlobeNewsWire • 09/01/23
PepGen Reports Second Quarter 2023 Financial Results and Recent Corporate DevelopmentsGlobeNewsWire • 08/08/23
PepGen Inc. Provides Update on Planned Initiation of Phase 1 Study of PGN-EDODM1 in Myotonic Dystrophy Type 1GlobeNewsWire • 06/13/23
PepGen Inc. Announces Clinical Hold in the U.S. on IND Application to Initiate a Phase 1 Study of PGN-EDODM1 for Myotonic Dystrophy Type 1 (DM1)GlobeNewsWire • 05/30/23
PepGen Announces Clearance by Health Canada of CTA for PGN-EDO51 to Begin the Phase 2 Clinical Trial, CONNECT1-EDO51, for the Treatment of Duchenne Muscular DystrophyGlobeNewsWire • 05/18/23
PepGen Reports First Quarter 2023 Financial Results and Recent Corporate DevelopmentsGlobeNewsWire • 05/11/23
PepGen to Participate in the Bank of America Securities 2023 Healthcare ConferenceGlobeNewsWire • 05/04/23
PepGen Announces Upcoming Data Presentations at the 2023 American Academy of Neurology Annual MeetingGlobeNewsWire • 04/17/23